

INDEX

Note: Page numbers followed by “f” denote figures; “t” tables.

- AASK (African American Study of Kidney Disease and Hypertension), 25, 122-124, 123f, 124t
- Abnormal imaging tests, 15-16
- Abnormal urinary sediment, 15
- Abnormalities, structural, 13-16
- Absorption, drugs, 245-249
- Access, 229-236
 - evaluations, 233-236, 234f
 - vascular, 229-232
 - AVF, 233-236
 - AVGs and, 229, 236
 - fundamental concepts for, 233
 - hemodialysis access evaluations, 233-236, 234f
 - reference resources for, 236
 - USRDS data for, 233
- Accupril (quinapril), 162t
- ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects.
 - See ATLANTIS (ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects).
- ACEIs (angiotensin-converting enzyme inhibitors), 97-101, 98t-100t, 102f-104f, 115-131, 118f, 124f, 126f-131f, 159-173, 162t, 163f, 169t-171t, 179-181, 187, 193-199, 230-232, 231t, 250t-251t
- Aceon (perindopril), 162t
- Acetohexamide, 248t
- Acetylated metabolites, 248t
- Acidosis, metabolic, 229-232
 - consequences, 230t
 - drug-related causes, 231t
 - fundamental concepts for, 229-230
 - reference resources for, 232
- ACRs (albumin to creatinine ratios), 178-181
- ADA (American Diabetes Association), 23, 65-67, 66f
- Adverse reactions, drug, 245-249

African American Study of Kidney Disease and Hypertension. *See* AASK (African American Study of Kidney Disease and Hypertension).

Agents, drug. *See* Specific drugs, drug agents, and drug classes.

Aggregation, familial, 49

AHA (American Heart Association), 241

AIPRI (Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency) study, 117-120, 118f-120f, 169t

Albumin to creatinine ratios. *See* ACRs (albumin to creatinine ratios).

Albuminuria, 137t

Alfacalcidol, oral, 224-225, 224t

α -Blockers, 250t-251t

Altace (ramipril), 117, 120f, 122-124, 123f, 124t, 162t

Aluminum carbonate, 218-225, 219t

Aluminum hydroxide, 218-225, 219t

American Diabetes Association. *See* ADA (American Diabetes Association).

American Heart Association. *See* AHA (American Heart Association).

Amiloride, 230-232, 231t

Amlodipine, 90f-91f, 92, 123-124t

ANBPS (Australian National Blood Pressure Study), 114f

Anemia management, 185-208

- assessments for, 186-187
- early treatment benefits for, 187
- fundamental concepts for, 185-186
- iron repletion and, 199-204, 200t, 202f
- pharmacotherapy options for, 190-199, 191t, 192f-193f, 196f-197f, 198t
- reference resources for, 204-208
- target Hb levels, 189
- therapy goals and, 189

Angiotensin-converting enzyme inhibitors. *See* ACEIs (angiotensin-converting enzyme inhibitors).

Angiotensin II receptor blockers. *See* ARBs (angiotensin II receptor blockers).

Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency study. *See* AIPRI (Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency) study.

Anorexia, 229-230

Antacids, 250t-251t

Antibiotics, 250t-251t

Antihypertensives, 109-134, 110f-111f, 116f-124f, 126f-131f, 159-176

Aranesp (darbepoetin alfa), 190-199, 191t, 192f-193f, 196f-197f, 198t

ARBs (angiotensin II receptor blockers), 93-97, 106f-107f, 115, 125-126, 126f, 127-131, 127t, 128f-131f, 161-173, 162t, 163f, 168t-171t, 179-181, 193-199, 230-232, 231t, 250t-251t

Arteriovenous fistula. *See* AVF (arteriovenous fistula).

Arteriovenous grafts. *See* AVGs (arteriovenous grafts).

Asevelamer HCl, 218-225, 219t

Assessments, 179f, 186-187

- for anemia management, 186-187
- for proteinuria management, 179f

Atacand (candesartan), 162t

ATLANTIS (ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects), 102f-103f

Australian National Blood Pressure Study. *See* ANBPS (Australian National Blood Pressure Study).

Avapro (irbesartan), 89-92, 90f-91f, 93-97, 96f, 162t, 165

AVF (arteriovenous fistula), 229-232

- AVF, 233-236
- AVGs and, 229, 236
- fundamental concepts for, 233
- hemodialysis access evaluations, 233-236, 234f
- reference resources for, 236
- USRDS data for, 233

AVGs (arteriovenous grafts), 229, 236

Azathioprine, 248t

Barbiturates, 247

Basic concepts. *See* Fundamental concepts.

Benazepril (Lotensin), 117-120, 118f-120f, 162t

Benicar (olmesartan), 162t

β -Blockers, 123-124, 123f, 124t, 170, 230-232, 231t

- Bile acid sequestrants, 140t-141t
- Binders, phosphate, 218-225, 219t
- Bioavailability, drugs, 245-249
- Bone disease, renal, 209-228
 - calcium, normal physiology of, 209-212, 211f
 - fundamental concepts for, 209
 - hyperparathyroidism, 212-225
 - calcium/phosphorus balance abnormalities, 214-225, 215f, 216t-219t, 221t, 223f, 224t
 - clinical manifestations of, 216t
 - development of, 215
 - foods, low-phosphorus vs high-phosphorus, 218t
 - pathophysiology of, 212-214, 213f
 - phosphate binders and, 219
 - vitamin D supplementation and, 220-222, 221t
 - phosphorus homeostasis, 209-212, 211f
 - PTH and, 210-225
 - reference resources for, 226-228
- Calcium, 123-124, 152, 209-225
 - calcium acetate, 218-225, 219t
 - calcium carbonate, 218-225, 219t
 - calcium/phosphorus balance abnormalities, 214-225, 215f, 216t-219t, 221t, 223f, 224t
 - channel blockers, dihydropyridine, 123-124, 123f, 124t
 - metabolism of, 152
 - normal physiology of, 209-212, 211f
- Candesartan (Atacand), 162t
- Capoten (captopril), 162t
- Captopril (Capoten), 162t
- Cardiac drugs, 250t-251t
- Cardiovascular disease. *See* CVD (cardiovascular disease).
- Cardiovascular risk factors, 135-158
 - calcium metabolism, 152
 - CVD risk factors and, 135-136, 136f
 - dyslipidemia, 136-145, 139t-144t
 - fundamental concepts for, 135-136
 - hyperhomocystenemia, 151-152
 - inflammation, 152
 - malnutrition, 152
 - phosphorus metabolism, 152
 - PTH levels and, 152
- Cardiovascular risk factors (*continued*)
 - reference resources for, 154-157
 - sleep disturbances, 152
 - smoking cessation, 145-146
 - thrombogenic markers, 152
 - TLCs for, 144t
 - traditional vs nontraditional, 137t, 151-153
 - weight, obesity, and metabolic syndrome and, 147-151, 148t
- Care guidelines, CKD stages, 266t-267t
- Care plan components, 268
- Central nervous system drugs, 250t-251t
- Chlorophenoxyisobutyric acid, 248t
- Ciontti and Zuchelli lisinopril study, 120-122, 121f-122f
- CKD stages, 266t-267t
- CKD (chronic kidney disease) topics. *See also under individual topics.*
 - anemia management, 185-208
 - cardiovascular risk factors, 135-158
 - descriptions and definitions, 13-18
 - detection and GFR estimation, 19-35
 - diabetes risk factors, 63-108
 - dialysis preparation, 255-261
 - disease progression, 53-61
 - epidemiology, 37-51
 - fundamental concepts, 3-18. *See also* Fundamental concepts.
 - hypertension risk factors, 109-134
 - joint management/CKD clinics, 263-270
 - metabolic acidosis risk factors, 229-232
 - proteinuria management, 177-184
 - RAAS blockades, 159-176
 - reference resources for. *See* Reference resources.
 - renal bone disease prevention, 209-228
 - therapies, 237-254
 - diet and nutritional therapies, 237-244
 - drug-dosing considerations, 245-254
 - vascular access and AVF, 229-232
- Classes, drug. *See* Specific drugs, drug agents, and drug classes.
- Clinic management issues, 263-270
 - care plan components, 268

- Clinic management issues (*continued*)
 fundamental concepts for, 263
 goals for, 263-264
 optimal care guidelines, CKD stages and, 266t-267t
 patient education, 264, 268t, 269
 reference resources for, 270
 referrals, 264, 269
 role-related issues, 263-265
 of multidisciplinary teams, 264-265
 of nephrologists, 263-265
 of PCPs, 263-265
- Clinical trials and research studies. *See also under specific trial names.*
 AASK, 122-124, 123f, 124t
 AIPRI study, 117-120, 118f-120f, 169t
 ANBPS, 114f
 ATLANTIS, 102f-103f
 Ciontti and Zuchelli lisinopril study, 120-122, 121f-122f
 COOPERATE, 125-126, 126f, 128f
 DCCT, 73-85, 74t-75t, 76f-80f, 82t-83t, 84f
 diabetes risk factors and, 65-97
 ESPRIT, 102f-103f
 EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes, 102f-103f
 GFR estimation in, 19. *See also* GFR (glomerular filtration rate) estimation.
 IDNT, 89-92, 90f-91f
 IRMA, 93, 96-97, 96f
 ISMG, 102f-103f
 MDNSG, 102f-103f
 MDRD study, 109, 115, 239, 249-254
 NECP-ATP III, 137-145, 139t-144t, 147-149, 148t
 NHANES III, 42-48, 67, 71, 109, 144t, 185-186
 PRIMA, 102f-103f
 REIN, 115-117, 116f, 167
 RENAAL study, 59-61, 61t, 92, 94t-95t
 Sys-Eur, 114f
 UKPDS, 85-89, 86t-88t
 Clofibrate, 247t-248t
 Cockcroft-Gault equations, 24, 249-252
- Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Nondiabetic Renal Disease. *See* COOPERATE (Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Nondiabetic Renal Disease).
- Contraindications, RAAS blockades, 172-173
- COOPERATE (Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Nondiabetic Renal Disease), 125-126, 126f
- COX (cycooxygenase)-2 inhibitors, 165, 170
- Cozaar (losartan), 92-93, 125-126, 126f, 162t, 165
- CPG (Clinical Practice Guideline) on Appropriate Patient Preparation for Renal Replacement Therapy, 258-259
- Cumulative risks, 38-41
- CVD (cardiovascular disease), 37, 48, 135-136, 241-243
 incidence and prevalence of, 37, 48
 lipid metabolism and, 241-243
 risk factors, 135-136, 136f. *See also* Cardiovascular risk factors.
- Cyooxygenase-2 inhibitors. *See* COX (cycooxygenase)-2 inhibitors.
- Darbepoetin alfa (Aranesp), 190-199, 191t, 192f-193f, 196f-197f, 198t
- DASH Diet plans, 112-114, 114f
- DCCT (Diabetes Control and Complications Trial), 73-85, 74t-75t, 76f-80f, 82t-83t, 84f
- Desacetylrifampin, 248t
- Descriptions and definitions, 13-18
- Detection and GFR estimation, 19-35
 fundamental concepts for, 19
 GFR estimation, 19-35
 24-hour creatinine clearance, 19
 in clinical trials, 19
 Cockcroft-Gault equation, 24
 descriptions of, 19
 equations for, 23-34
 inaccuracy of, 21-23, 22f, 23t
 Iothalamate markers and, 19
 MDRD, 23-32, 28t-29t, 30f 31t. *See also* MDRD (Modification of Diet in Renal Disease) study.

Detection and GFR estimation, GFR estimation (*continued*)
 serum creatinine-based methods of, 19-32, 22f, 23t,
 28t-29t, 30f, 31t
 reference resources for, 34-35
DexFerrum, 200-204, 200t
Diabetes Control and Complications Trial. *See* DCCT
 (Diabetes Control and Complications Trial).
Diabetes risk factors, 63-108
 clinical trials and, 65-97. *See also* Clinical trials and
 research studies.
 diabetic kidney disease, 65-97
 ADA Guidelines for Screening and Diagnosis, 65-67, 66f
 diagnoses of, 65-72, 66f, 68t-72t
 nephropathy, diabetic, 67-72
 neuropathy, diabetic, 67-72
 prevention of, 72-97, 74t-75t, 76f-80f, 82t-83t, 84f,
 86f-88f, 90f-91f, 94t-96t
 retinopathy, diabetic, 67-72
 type 1 diabetes mellitus, 67
 type 2 diabetes mellitus, 67, 71
 fundamental concepts for, 63
 proteinuria and, 63-65, 64f
 RAAS blockades and, 97-101, 98t-101t, 102f-104f. *See*
 also RAAS (renin-angiotensin-aldosterone system)
 blockades.
 reference resources for, 101-108
Dialysis access evaluations, 233-236, 234f
Dialysis preparation, 255-261
 CPG on Appropriate Patient preparation for Renal
 replacement Therapy, 258-259
 fundamental concepts for, 255
 initiation timing, 258-259
 Medicare ESRD program, 259-261
 modality selection, 256-258
 patient education for, 255-256
 reference resources for, 261
Diazepam, 247t-248t
Diazoxide, 247t
Diet and nutritional therapies, 237-244
 DASH Diet plans and, 112-114, 114f
 ESRD and, 237
 foods, low-phosphorus vs high-phosphorus, 218t

Diet and nutritional therapies (*continued*)
 fundamental concepts for, 237-239
 lipid metabolism and, 239-242, 240t, 242t
 CVD and, 241-243
 LDL vs HDL levels, 239-242, 242t
 malnutrition factors and, 238t
 MDRD, 239. *See also* MDRD (Modification of Diet in
 Renal Disease) study.
 reference resources for, 244
 vitamin and mineral requirements, 243
Dihydropyridine calcium channel blockers, 123-124, 123f,
 124t
Disease progression, 53-61
 fundamental concepts for, 53
 MDRD clinical relevance, 59-61, 59f, 61t
 progressive CKD models, 54-55, 56f
 reference resources for, 60
 risk factors for, 61t
 variable rates of, 55-58, 58f
Diuretics, 127-128, 168, 172
 loop, 172
 potassium-sparing, 230-232, 231t, 250t-251t
 thiazide, 128, 172
Divan (valsartan), 162t
Doxercalciferol, oral, 224-225, 224t
Drug-dosing considerations, 245-254
 absorption, 245-249
 adverse reactions, 245-249
 bioavailability, 245-249
 distribution volumes, 245-249
 dosing-specific issues, 249-254
 adjustments, 251-254
 Cockcroft-Gault equations and, 24, 249-252
 descriptions of, 249
 dosing steps, 249-254
 GFR and, 245-246, 252-254. *See also* GFR (Glomerular
 filtration rate) estimation.
 MDRD and, 249-254. *See also* MDRD (Modification of
 Diet in Renal Disease) study.
 Physicians' Desk Reference and, 254
 drug elimination, 245-249
 fundamental concepts for, 245

Drug-dosing considerations (*continued*)

pharmacodynamic and pharmacokinetic variables, 249-251t
pharmacokinetic changes and, 245-248, 247t-248t
reference resources for, 254
specific drugs, drug agents, and drug classes. *See also under specific names.*
 α -blockers, 250t-251t
 β -blockers, 123-124, 123f, 124t, 170, 230-232, 231t
4-hydroxypropranolol, 248t
6-mercaptopurine, 248t
ACEIs, 97-101, 98t-100t, 102f-104f, 115-131, 118f, 124f, 126f-131f, 159-173, 162t, 163f, 169t-171t, 179-181, 187, 193-199, 230-232, 231t, 250t-251t
acetohexamide, 248t
acetylated metabolites, 248t
alfacalcidol, oral, 224-225, 224t
allopurinol, 248t
aluminum carbonate, 218-225, 219t
aluminum hydroxide, 218-225, 219t
amiloride, 230-232, 231t
amlodipine, 90f-91f, 92, 123-124t
antacids, 250t-251t
antibiotics, 250t-251t
antihypertensives, 109-134, 110f-111f, 116f-124f, 126f-131f, 159-176
ARBs, 93-97, 106f-107f, 115, 125-126, 126f, 127-131, 127t, 128f-131f, 161-173, 162t, 163f, 168t-171t, 179-181, 193-199, 230-232, 231t, 250t-251t
asevelamer HCl, 218-225, 219t
azathioprine, 248t
barbiturates, 247
benazepril (Lotensin), 117-120, 118f-120f, 162t
bile acid sequestrants, 140t-141t
calcium acetate, 218-225, 219t
calcium carbonate, 218-225, 219t
candesartan (Atacand), 162t
captopril (Capoten), 162t
cardiac drugs, 250t-251t
central nervous system drugs, 250t-251t
chlorophenoxyisobutyric acid, 248t
clofibrate, 247t-248t
COX-2 inhibitors, 165, 170

darbepoetin alfa (Aranesp), 190-199, 191t, 192f-193f, 196f-197f, 198t
desacetylrifampin, 248t
DexFerrum, 200-204, 200t
diazepam, 247t-248t
diazoxide, 247t
dihydropyridine calcium channel blockers, 123-124, 123f, 124t
diuretics, 127-128, 168, 172
doxercalciferol, oral, 224-225, 224t
enalapril (Vasotec), 162t
eplerenone, 230-232, 231t
EPO therapy, 190-204, 191t, 192f-193f, 196f-197f, 198t, 202t
epoetin alfa (Procrit), 190-199, 191t, 192f-193f, 196f-197f, 198t
eprosartan (Teveten), 162t
ferric gluconate, 200-204, 200t, 202f
ferric saccharate, 200t
Ferritin, 202-204, 202t
Ferrelecit, 200-204, 200t
furosemide, 247t
gemfibrozil, 140t-141t
glycinexylidide, 248t
heparin, 230-232, 231t
hydroxyhexamide, 248t
Imferon, 200-204, 200t
INFeD, 200-204, 200t
insulin, 148t, 247-249, 250t-251t
irbesartan (Avapro), 89-92, 90f-91f, 93-97, 96f, 162t, 165
iron dextran injections, 200-204, 200t
iron saccharate, 200-204, 200t
iron sucrose injections, 200-204, 200t, 202f
lanthanum carbonate, 218-225, 219t
laxatives, 250t-251t
lidocaine, 248t
lisinopril (Prinivil and Zestril), 120-122, 121f-131f, 162t
loop diuretics, 172
losartan (Cozaar), 92-93, 125-126, 126f, 162t, 165

Drug-dosing considerations, specific drugs, drug agents, and drug classes (*continued*)

- magaldrate, 218-225, 219t
- meperidine, 248t
- methotrexate, 247t
- metolazone, 247t
- metoprolol, 123-124, 123f, 124t
- mexiletine, 247t
- moexipril (Univasc), 162t
- multiple drugs, 250t-251t
- n-acetylprocainamide, 248t
- nicotinic acid, 140t-141t
- nitroprusside, 248t
- normeperidine, 248t
- NSAIDs, 164, 170, 230-232, 231t
- olmesartan (Benicar), 162t
- oxazepam, 248t
- oxypurinol, 248t
- paricalcitol, oral, 224-225, 224t
- penicillins, 247t, 250t-251t
- perindopril (Aceon), 162t
- phenytoin, 247t, 250t-251t
- phosphate binders, 218-225, 219t
- potassium-sparing diuretics, 230-232, 231t, 250t-251t
- probenecid, 247t
- procainamide, 248t
- propranolol, 248t, 250t-251t
- quinapril (Accupril), 162t
- RAAS blockers, 115, 159-176. *See also* RAAS (renin-angiotensin-aldosterone system) blockades.
- ramipril (Altace), 117, 120f, 122-124, 123f, 124t, 162t
- rifampin, 248t
- salicylates, 247t
- sodium ferric gluconate complex in sucrose injections, 200-204, 200t
- statins, 140t-141t
- steroids, 250t-251t
- sulfonamides, 247t-248t
- telmisartan (Micardis), 162t
- tetracyclines, 250t-251t
- thiazide diuretics, 128, 172
- thiocyanate, 248t

Drug-dosing considerations, specific drugs, drug agents, and drug classes (*continued*)

- trandolapril, 125-126, 126f
- triamterene, 247t
- valsartan (Divan), 162t
- vasodilators, 164
- Venofer, 200-204, 200t
- warfarin, 247t

Drugs. *See* Specific drugs, drug agents, and drug classes.

Dyslipidemia, 136-145, 139t-144t

Early treatment benefits, anemia, 187

Education, patient. *See* Patient education.

Electrolyte imbalances, 137t

Elimination, drug, 245-249

Enalapril (Vasotec), 162t

Endogenous erythropoietin, 190-199, 191t, 192f-193f, 196f-197f, 198t

End-stage renal disease. *See* ESRD (end-stage renal disease).

Epidemiology, 37-51

ESRD incidence and prevalence, 37-48

cumulative risks, 38-41

CVD and, 37, 48

descriptions of, 37

ESRD epidemic, relevance of, 41-42

incidence, 37-42, 39f, 40t, 41f

natural history, 45-48

prevalence, 42-48, 44t, 46t, 47f

racial disparities of, 45-46t

in U.S. populations, 43-45

USRDS data and, 37-48

fundamental concepts for, 37

high-risk groups, 48-50

descriptions of, 48-49

familial aggregation, 49

progressive CKD, 49-50

risk factors, 49-50

reference resources for, 50-51

Eplerenone, 230-232, 231t

EPO (erythropoietin) therapy, 190-204, 191t, 192f-193f, 196f-197f, 198t, 202t

- Epoetin alfa (Procrit), 190-199, 191t, 192f-193f, 196f-197f, 198t
- Eprosartan (Teveten), 162t
- Erythropoietin. *See* EPO (erythropoietin) therapy.
- ESPRIT (European Study of the Prevention of Renal Disease in Type I Diabetes), 102f-103f
- ESRD (end-stage renal disease), 15
- diet and nutritional therapies and, 237
 - fundamental concepts for, 15
 - incidence and prevalence of, 37-48
 - cumulative risks, 38-41
 - CVD and, 37, 48
 - descriptions of, 37
 - ESRD epidemic, relevance of, 41-42
 - incidence, 37-42, 39f, 40t, 41f
 - natural history, 45-48
 - prevalence, 42-48, 44t, 46t, 47f
 - racial disparities of, 45-46t
 - in U.S. populations, 43-45
 - USRDS data and, 37-48
- EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes, 102f-103f
- European Study of the Prevention of Renal Disease in Type I Diabetes. *See* ESPRIT (European Study of the Prevention of Renal Disease in Type I Diabetes).
- Familial aggregation, 49
- Ferric gluconate, 200-204, 200t, 202f
- Ferric saccharate, 200t
- Ferritin, 202-204, 202t
- Ferrlecit, 200-204, 200t
- Follow-ups, 181-182
- Foods, low-phosphorus vs high-phosphorus, 218t
- Fundamental concepts, 3-18. *See also under individual topics.*
- abnormal imaging tests, 15-16
 - abnormal urinary sediment, 15
 - for anemia management, 185-186
 - for cardiovascular risk factors, 135-136
 - CDK take-home points, 17-18
 - CKD definitions, 3
 - CKD stages, 16-17, 17t
- Fundamental concepts (*continued*)
- for detection and GFR estimation, 19
 - for diabetes risk factors, 63
 - for dialysis preparation, 255
 - for diet and nutritional therapies, 237-239
 - for disease progression, 53
 - for drug-dosing considerations, 245
 - for epidemiology, 37
 - ESRD, 15
 - GFR estimation, 16-17, 17t
 - for hypertension risk factors, 109-111, 110f-111f
 - for joint management/CKD clinics, 263
 - kidney damage, 13-16
 - for metabolic acidosis risk factors, 229-230
 - proteinuria, 14t, 15
 - for RAAS blockades, 159-161
 - reference resources for, 18
 - for renal bone disease prevention, 209
 - structural abnormalities, 13-16
 - for vascular access and AVF, 233
 - Furosemide, 247t
- Gemfibrozil, 140t-141t
- GFR (glomerular filtration rate) estimation, 19-35
- 24-hour creatinine clearance, 19
 - in clinical trials, 19
 - drug dosing and, 245-246, 252-254
 - equations for, 23-34
 - Cockcroft-Gault equation, 24
 - MDRD, 23-32, 28t-29t, 30f 31t. *See also* MDRD (Modification of Diet in Renal Disease) study.
 - fundamental concepts for, 16-17, 17t, 19
 - inaccuracy of, 21-23, 22f, 23t
 - Iothalamate markers and, 19
 - serum creatinine-based methods of, 19-32, 22f, 23t, 28t-29t, 30f, 31t
- Glomerular filtration rate. *See* GFR (glomerular filtration rate) estimation.
- Glycinexylidide, 248t
- Grafts, AVGs, 229, 236

- 4-Hydroxypropranolol, 248t
- 24-Hour creatinine clearance, 19
- Hb levels, target, 189
- HDL vs LDL levels, 137t, 239-242, 242t
- Hemodialysis access evaluations, 233-236, 234f
- Heparin, 230-232, 231t
- High-phosphorus vs low-phosphorus foods, 218t
- High-risk groups, 48-50
 - descriptions of, 48
 - familial aggregation, 49
 - progressive CKD, 49-50
 - risk factors, 49-50
- Hydroxyhexamide, 248t
- Hyperhomocystenemia, 151-152
- Hyperkalemia, 168-172, 169t-171t, 231-231t
- Hyperparathyroidism, 212-225
 - calcium/phosphorus balance abnormalities, 214-225, 215f, 216t-219t, 221t, 223f, 224t
 - clinical manifestations of, 216t
 - development of, 215
 - foods, low-phosphorus vs high-phosphorus, 218t
 - pathophysiology of, 212-214, 213f
 - phosphate binders and, 219
 - vitamin D supplementation and, 220-222, 221t
- Hypertension risk factors, 109-134
 - clinical trials and research studies of, 114-131, 116f, 118f-123f, 124t, 126f. *See also* Clinical trials and research studies.
 - DASH Diet plans and, 112-114, 114f
 - fundamental concepts for, 109-111, 110f-111f
 - MDRD and, 109-111, 110f-111f, 115. *See also* MDRD (Modification of Diet in Renal Disease) study.
 - prevalence of, 109-111, 110f-111f
 - primary prevention, 112-114, 114f
 - reference resources for, 131-134
 - secondary prevention, 114-131, 116f, 118f-123f, 124t, 126f
 - treatment intensification and, 126-131, 127t, 128f-131f
- IDNT (Irbesartan Diabetic Nephropathy Trial), 89-92, 90f-91f
- Imaging tests, abnormal, 15-16
- Imferon, 200-204, 200t
- Inaccuracy, GFR estimation, 21-23, 22f, 23t
- Incidence and prevalence, 37-48. *See also* Epidemiology.
- INFEd, 200-204, 200t
- Inflammation, 152
- Insulin, 148t, 247-249, 250t-251t
- Introductory concepts. *See* Fundamental concepts.
- Iothalamate markers, 19
- Irbesartan (Avapro), 89-92, 90f-91f, 93-97, 96f, 162t, 165
- Irbesartan Diabetic Nephropathy Trial. *See* IDNT (Irbesartan Diabetic Nephropathy Trial).
- Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria. *See* IRMA (Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria).
- IRMA (Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria), 93, 96-97, 96f
- Iron dextran injections, 200-204, 200t
- Iron repletion, 199-204, 200t, 202f
- Iron saccharate, 200-204, 200t
- Iron sucrose injections, 200-204, 200t, 202f
- ISMG (Italian Microalbuminuria Study Group), 102f-103f
- Italian Microalbuminuria Study Group. *See* ISMG (Italian Microalbuminuria Study Group).
- JNC 7 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), 20, 23, 112-114, 114f
- Joint management/CKD clinics, 263-270
 - care plan components, 268
 - fundamental concepts for, 263
 - goals for, 263-264
 - optimal care guidelines, CKD stages and, 266t-267t
 - patient education, 264, 268t, 269
 - reference resources for, 270
 - referrals, 264, 269
 - role-related issues, 263-265
 - of multidisciplinary teams, 264-265
 - of nephrologists, 263-265
 - of PCPs, 263-265
- K/DOQI (Kidney Disease Outcome Quality Initiative) guidelines, 140t-141t, 177-178

- Lanthanum carbonate, 218-225, 219t
- Laxatives, 250t-251t
- LDL vs HDL levels, 137t, 239-242, 242t
- Lidocaine, 248t
- Lipid metabolism, 239-242, 240t, 242t
- Lisinopril (Prinivil and Zestril), 120-122, 121f-131f, 162t
- Loop diuretics, 172
- Losartan (Cozaar), 92-93, 125-126, 126f, 162t, 165
- Lotensin (benazepril), 117-120, 118f-120f, 162t
- Low-phosphorus vs high-phosphorus foods, 218t
- 6-Mercaptopurine, 248t
- Magaldrate, 218-225, 219t
- Malnutrition, 137t, 152, 229-230
- Malnutrition factors, 238t
- MDNSG (Melbourne Diabetic Nephropathy Study Group), 102f-103f
- MDRD (Modification of Diet in Renal Disease) study, 23-34, 109, 115, 239, 249-254
- clinical relevance of, 59-61, 59f, 61t
 - disease progression factors and, 59-61, 59f, 61t
 - GFR estimation and, 23-34. *See also* GFR (glomerular filtration rate) estimation.
 - accuracy of, 25, 28t-29t
 - acute renal failure and, 33
 - considerations for, 32-34
 - descriptions of, 23-24
 - equations for, 24-25
 - four-variable equation for, 25-32
 - for healthy individuals, 26-27
 - identification uses of, 30-31, 31t
 - laboratory creatinine calibration and, 32
 - limitations of, 25
 - monitoring uses of, 30-31, 31t
 - non-CKD conditions and, 33-34
 - persistent kidney damage vs decreased GFR, 34
 - sensitivity of, 27-32, 28t-29t, 30f, 31t
 - specificity of, 27-32, 28t-29t, 30f, 31t
 - validation of, 25
 - hypertension risk factors and, 109-111, 110f-111f, 115
- Medicare ESRD program, 259-261
- Medication-related considerations. *See* Drug-dosing considerations.
- Melbourne Diabetic Nephropathy Study Group. *See* MDNSG (Melbourne Diabetic Nephropathy Study Group).
- Meperidine, 248t
- Metabolic acidosis risk factors, 229-232
- consequences, 230t
 - drug-related causes, 231t
 - fundamental concepts for, 229-230
 - reference resources for, 232
- Metabolic syndrome and obesity, 147-151, 148t
- Methotrexate, 247t
- Metolazone, 247t
- Metoprolol, 123-124, 123f, 124t
- Mexiletine, 247t
- Micardis (telmisartan), 162t
- Mineral and vitamin requirements, 243
- Modality selection, dialysis, 256-258
- Models, progressive, 54-55, 56f
- Modification of Diet in Renal Disease study. *See* MDRD (Modification of Diet in Renal Disease) study.
- Moexipril (Univasc), 162t
- Multidisciplinary team roles, 264-265
- Multiple drugs, 250t-251t
- Muscle breakdown, 230t
- N-acetylprocainamide, 248t
- National Cholesterol Education Program guidelines. *See* NCEP (National Cholesterol Education Program) guidelines.
- National Cholesterol Education Program-Adult Treatment Panel III. *See* NECP-ATP III (National Cholesterol Education Program-Adult Treatment Panel III).
- National Health and Nutrition Examination Survey III. *See* NHANES (National Health and Nutrition Examination Survey) III.
- National Institute of Diabetes and Diseases of the Kidney. *See* NIDDK (National Institute of Diabetes and Diseases of the Kidney).
- National Kidney Disease Education Program, 24-25

National Kidney Foundation. *See* NKF (National Kidney Foundation).

Natural history, 45-48

NCEP (National Cholesterol Education Program) guidelines, 136-137

NECP-ATP III (National Cholesterol Education Program-Adult Treatment Panel III), 137-145, 139t-144t, 147-151, 148t

Nephrologists, 263-265

Nephrology referrals, 181-182

Nephropathy, diabetic, 67-72

Neuropathy, diabetic, 67-72

NHANES (National Health and Nutrition Examination Survey) III, 42-48, 67, 71, 109, 144t, 185-186

Nicotinic acid, 140t-141t

NIDDK (National Institute of Diabetes and Diseases of the Kidney), 24-25

Nitroprusside, 248t

NKF (National Kidney Foundation), 13, 20, 23, 177

Nonsteroidal anti-inflammatory drugs. *See* NSAIDs (nonsteroidal anti-inflammatory drugs).

Normeperidine, 248t

NSAIDs (nonsteroidal anti-inflammatory drugs), 164, 170, 230-232, 231t

Nutritional and diet therapies, 237-244

 DASH Diet plans and, 112-114, 114f

 ESRD and, 237

 foods, low-phosphorus vs high-phosphorus, 218t

 fundamental concepts for, 237-239

 lipid metabolism and, 239-242, 240t, 242t

 CVD and, 241-243

 LDL vs HDL levels, 239-242, 242t

 malnutrition factors and, 238t

 MDRD, 239. *See also* MDRD (Modification of Diet in Renal Disease) study.

 reference resources for, 244

 vitamin and mineral requirements, 243

Obesity and metabolic syndrome, 147-151, 148t

Olmesartan (Benicar), 162t

Optimal care guidelines, CKD stages, 266t-267t

Oral alfacalcidol, 224-225, 224t

Oral Doxercalciferol, 224-225, 224t

Oral paricalcitol, 224-225, 224t

Osteopenia, 229-230, 230t

Overviews. *See* Fundamental concepts.

Oxazepam, 248t

Oxypurinol, 248t

PARADE (Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination), 177-178

Parathyroid hormone levels. *See* PTH (parathyroid hormone) levels.

Paricalcitol, oral, 224-225, 224t

Patient education, 264, 268t, 269

 for dialysis preparation, 255-256

PCP (primary care physician) roles, 263-265

Penicillins, 247t, 250t-251t

Perindopril (Aceon), 162t

Pharmacodynamic and pharmacokinetic variables, 249-251t

Pharmacokinetic changes, 245-248, 247t-248t

Pharmacologic therapy considerations, 245-254. *See also* Drug-dosing considerations.

 absorption, 245-249

 adverse reactions, 245-249

 for anemia management, 190-199, 191t, 192f-193f, 196f-197f, 198t

 bioavailability, 245-249

 distribution volumes, 245-249

 dosing-specific issues, 249-254

 adjustments, 251-254

 Cockcroft-Gault equations and, 24, 249-252

 dosing steps, 249-254

 GFR and, 252-254. *See also* GFR (Glomerular filtration rate) estimation.

 MDRD and, 249-254. *See also* MDRD (Modification of Diet in Renal Disease) study.

 Physicians' Desk Reference and, 254

 drug elimination, 245-249

 fundamental concepts for, 245

 pharmacodynamic and pharmacokinetic variables, 249-251t

 pharmacokinetic changes and, 245-248, 247t-248t

 reference resources for, 254

Pharmacologic therapy considerations (*continued*)
specific drugs, drug agents, and drug classes. *See also*
under individual names.

α -blockers, 250t-251t
 β -blockers, 123-124, 123f, 124t, 170, 230-232, 231t
4-hydroxypropranolol, 248t
6-mercaptopurine, 248t
ACEIs, 97-101, 98t-100t, 102f-104f, 115-131, 118f,
124f, 126f-131f, 159-173, 162t, 163f, 169t-171t,
179-181, 187, 193-199, 230-232, 231t, 250t-251t
acetohexamide, 248t
acetylated metabolites, 248t
alfacalcidol, oral, 224-225, 224t
allopurinol, 248t
aluminum carbonate, 218-225, 219t
aluminum hydroxide, 218-225, 219t
amiloride, 230-232, 231t
amlodipine, 90f-91f, 92, 123-124t
antacids, 250t-251t
antibiotics, 250t-251t
antihypertensives, 109-134, 110f-111f, 116f-124f,
126f-131f, 159-176
ARBs, 93-97, 106f-107f, 115, 125-126, 126f, 127-131,
127t, 128f-131f, 161-173, 162t, 163f, 168t-171t,
179-181, 193-199, 230-232, 231t, 250t-251t
asevelamer HCl, 218-225, 219t
azathioprine, 248t
barbiturates, 247
benazepril (Lotensin), 117-120, 118f-120f, 162t
bile acid sequestrants, 140t-141t
calcium acetate, 218-225, 219t
calcium carbonate, 218-225, 219t
candesartan (Atacand), 162t
captopril (Capoten), 162t
cardiac drugs, 250t-251t
central nervous system drugs, 250t-251t
chlorophenoxyisobutyric acid, 248t
clofibrate, 247t-248t
COX-2 inhibitors, 165, 170
darbepoetin alfa (Aranesp), 190-199, 191t, 192f-193f,
196f-197f, 198t
desacetylirifampin, 248t

Pharmacologic therapy considerations, specific drugs,
drug agents, and drug classes (*continued*)

DexFerrum, 200-204, 200t
diazepam, 247t-248t
diazoxide, 247t
dihydropyridine calcium channel blockers, 123-124,
123f, 124t
diuretics, 127-128, 168, 172
doxercalciferol, oral, 224-225, 224t
enalapril (Vasotec), 162t
eplerenone, 230-232, 231t
EPO therapy, 190-204, 191t, 192f-193f, 196f-197f,
198t, 202t
epoetin alfa (Procrit), 190-199, 191t, 192f-193f,
196f-197f, 198t
eprosartan (Teveten), 162t
ferric gluconate, 200-204, 200t, 202f
ferric saccharate, 200t
Ferritin, 202-204, 202t
Ferrelecit, 200-204, 200t
furosemide, 247t
gemfibrozil, 140t-141t
glycinexylidide, 248t
heparin, 230-232, 231t
hydroxyhexamide, 248t
Imferon, 200-204, 200t
INFeD, 200-204, 200t
insulin, 148t, 247-249, 250t-251t
irbesartan (Avapro), 89-92, 90f-91f, 93-97, 96f, 162t, 165
iron dextran injections, 200-204, 200t
iron saccharate, 200-204, 200t
iron sucrose injections, 200-204, 200t, 202f
lanthanum carbonate, 218-225, 219t
laxatives, 250t-251t
lidocaine, 248t
lisinopril (Prinvil and Zestril), 120-122, 121f-131f, 162t
loop diuretics, 172
losartan (Cozaar), 92-93, 125-126, 126f, 162t, 165
magaldrate, 218-225, 219t
meperidine, 248t
methotrexate, 247t
metolazone, 247t

Pharmacologic therapy considerations, specific drugs,
drug agents, and drug classes (*continued*)

metoprolol, 123-124, 123f, 124t
mexiletine, 247t
moexipril (Univasc), 162t
multiple drugs, 250t-251t
n-acetylprocainamide, 248t
nicotinic acid, 140t-141t
nitroprusside, 248t
normeperidine, 248t
NSAIDs, 164, 170, 230-232, 231t
olmesartan (Benicar), 162t
oxazepam, 248t
oxypurinol, 248t
paricalcitol, oral, 224-225, 224t
penicillins, 247t, 250t-251t
perindopril (Aceon), 162t
phenytoin, 247t, 250t-251t
phosphate binders, 218-225, 219t
potassium-sparing diuretics, 230-232, 231t, 250t-251t
probenecid, 247t
procainamide, 248t
propranolol, 248t, 250t-251t
quinapril (Accupril), 162t
RAAS blockers, 115, 159-176. *See also* RAAS (renin-angiotensin-aldosterone system) blockades.
ramipril (Altace), 117, 120f, 122-124, 123f, 124t, 162t
rifampin, 248t
salicylates, 247t
sodium ferric gluconate complex in sucrose injections, 200-204, 200t
statins, 140t-141t
steroids, 250t-251t
sulfonamides, 247t-248t
telmisartan (Micardis), 162t
tetracyclines, 250t-251t
thiazide diuretics, 128, 172
thiocyanate, 248t
trandolapril, 125-126, 126f
triamterene, 247t
valsartan (Divan), 162t
vasodilators, 164

Pharmacologic therapy considerations, specific drugs,
drug agents, and drug classes (*continued*)

Venofer, 200-204, 200t
warfarin, 247t
Phenytoin, 247t, 250t-251t
Phosphate binders, 218-225, 219t
Phosphorus homeostasis, 209-212, 211f
Phosphorus metabolism, 152
Phosphorus/calcium balance abnormalities, 214-225, 215f, 216t-219t, 221t, 223f, 224t
Physicians' Desk Reference, 254
Potassium-sparing diuretics, 230-232, 231t, 250t-251t
Prevalence and incidence. *See* Epidemiology.
Prevention. *See also under individual topics.*
diabetic kidney disease, 72-97, 74t-75t, 76f-80f, 82t-83t, 84f, 86f-88f, 90f-91f, 94t-96t
hypertension risk, 112-131, 114f, 116f, 118f-123f, 124t, 126f
primary, 112-114, 114f
secondary, 114-131, 116f, 118f-123f, 124t, 126f
of renal bone disease, 209-228
PRIMA (Project with Ramipril on Insulin dependent patients with Microalbuminuria), 102f-103f
Primary care physician roles. *See* PCP (primary care physician) roles.
Primary prevention, hypertension risk, 112-114, 114f
Prinivil (lisinopril), 120-122, 121f-131f, 162t
Probenecid, 247t
Procainamide, 248t
Procrit (epoetin alfa), 190-199, 191t, 192f-193f, 196f-197f, 198t
Progression, disease, 53-61
fundamental concepts for, 53
MDRD clinical relevance, 59-61, 59f, 61t
progressive CKD models, 54-55, 56f
reference resources for, 60
risk factors for, 61t
variable rates of, 55-58, 58f
Progressive CKD, 49-50, 54-55, 56f
descriptions of, 49-50
models of, 54-55, 56f

Project with Ramipril on Insulin dependent patients with Microalbuminuria. *See* PRIMA (Project with Ramipril on Insulin dependent patients with Microalbuminuria).

Propranolol, 248t, 250t-251t

Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination. *See* PARADE (Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination).

Proteinuria management, 14t, 15, 177-181

ACRs, 178-181

assessments and, 179f

diabetes risk factors and, 63-65, 64f

follow-ups and, 181-182

fundamental concepts for, 14t, 15, 177-181

K/DOQI guidelines, 177-178

nephrology referrals and, 181-182

PARADE and, 177-178

reference resources for, 182-184

PTH (parathyroid hormone) levels, 152, 210-225

Quinapril (Accupril), 162t

RAAS (renin-angiotensin-aldosterone system) blockades, 159-176

contraindications for, 172-173

fundamental concepts for, 159-161

reference resources for, 173-175

therapies using, 161-172

ACEIs, aldosterone and, 168-170, 169t-170t

ACEIs, first-dose hypertension and, 165-166

ACEIs, GFR estimation and, 161-164, 162t, 163f

ACEIs, hyperkalemia and, 168-172, 169t-171t

ACEIs, initiation of, 165-166

ACEIs, treatment goals and, 166-167

descriptions of, 161

Racial disparities, ESRD incidence and prevalence, 45-46t

Ramipril (Altace), 117, 120f, 122-124, 123f, 124t, 162t

Ramipril Efficacy in Nephropathy. *See* REIN (Ramipril Efficacy in Nephropathy).

Reduction in Endpoints in Noninsulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan. *See* RENAAL (Reduction in Endpoints in Noninsulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan) study.

Reference resources. *See also under individual topics.*

for anemia management, 204-208

for cardiovascular risk factors, 154-157

for detection and GFR estimation, 34-35

for diabetes risk factors, 101, 104-105

for dialysis preparation, 261

for diet and nutritional therapies, 244

for disease progression, 60

for drug-dosing considerations, 254

for epidemiology, 50-51

for diet and nutritional therapies, 244

for fundamental concepts, 18

for hypertension risk factors, 131-134

for joint management/CKD clinics, 270

for metabolic acidosis risk factors, 232

for proteinuria management, 182-184

for RAAS blockades, 173-175

for renal bone disease prevention, 226-228

for vascular access and AVF, 236

Referrals, 181-182, 264, 269

REIN (Ramipril Efficacy in Nephropathy), 115-117, 116f, 167

RENAAL (Reduction in Endpoints in Noninsulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan) study, 59-61, 61t, 92, 94t-95t

Renal bone disease prevention, 209-228

calcium, normal physiology of, 209-212, 211f

fundamental concepts for, 209

hyperparathyroidism, 212-225

calcium/phosphorus balance abnormalities, 214-225, 215f, 216t-219t, 221t, 223f, 224t

clinical manifestations of, 216t

development of, 215

foods, low-phosphorus vs high-phosphorus, 218t

pathophysiology of, 212-214, 213f

phosphate binders and, 219

vitamin D supplementation and, 220-222, 221t

Renal bone disease prevention (*continued*)

phosphorus homeostasis, 209-212, 211f

PTH and, 210-225

reference resources for, 226-228

Renal Physicians Association, 258-259

Renin-angiotensin-aldosterone system blockades.

See RAAS (renin-angiotensin-aldosterone system) blockades.

Repletion, iron, 199-204, 200t, 202f

Research studies. *See* Clinical trials and research studies.

Retinopathy, diabetic, 67-72

Rifampin, 248t

Salicylates, 247t

Secondary prevention, hypertension risk, 114-131, 116f, 118f-123f, 124t, 126f

Sediment, urinary, 15

Sequestrants, bile acid, 140t-141t

Serum creatinine-based methods, GFR estimation, 19-32, 22f, 23t, 28t-29t, 30f, 31t

Sleep disturbances, 137t, 152

Smoking cessation, 145-146

Sodium ferric gluconate complex in sucrose injections, 200-204, 200t

Specific drugs, drug agents, and drug classes. *See also under individual names.*

α -blockers, 250t-251t

β -blockers, 123-124, 123f, 124t, 170, 230-232, 231t

4-hydroxypropranolol, 248t

6-mercaptopurine, 248t

ACEIs, 97-101, 98t-100t, 102f-104f, 115-131, 118f, 124f, 126f-131f, 159-173, 162t, 163f, 169t-171t, 179-181, 187, 193-199, 230-232, 231t, 250t-251t

acetohexamide, 248t

acetylated metabolites, 248t

alfacalcidol, oral, 224-225, 224t

allopurinol, 248t

aluminum carbonate, 218-225, 219t

aluminum hydroxide, 218-225, 219t

amiloride, 230-232, 231t

amlodipine, 90f-91f, 92, 123-124t

antacids, 250t-251t

Specific drugs, drug agents, and drug classes (*continued*)

antibiotics, 250t-251t

antihypertensives, 109-134, 110f-111f, 116f-124f, 126f-131f, 159-176

ARBs, 93-97, 106f-107f, 115, 125-126, 126f, 127-131, 127t, 128f-131f, 161-173, 162t, 163f, 168t-171t, 179-181, 193-199, 230-232, 231t, 250t-251t

asevelamer HCl, 218-225, 219t

azathioprine, 248t

barbiturates, 247

benazepril (Lotensin), 117-120, 118f-120f, 162t

bile acid sequestrants, 140t-141t

calcium acetate, 218-225, 219t

calcium carbonate, 218-225, 219t

candesartan (Atacand), 162t

captopril (Capoten), 162t

cardiac drugs, 250t-251t

central nervous system drugs, 250t-251t

chlorophenoxyisobutyric acid, 248t

clofibrate, 247t-248t

COX-2 inhibitors, 165, 170

darbepoetin alfa (Aranesp), 190-199, 191t, 192f-193f, 196f-197f, 198t

desacetyl rifampin, 248t

DexFerrum, 200-204, 200t

diazepam, 247t-248t

diazoxide, 247t

dihydropyridine calcium channel blockers, 123-124, 123f, 124t

diuretics, 127-128, 168, 172

doxercalciferol, oral, 224-225, 224t

enalapril (Vasotec), 162t

eplerenone, 230-232, 231t

EPO therapy, 190-204, 191t, 192f-193f, 196f-197f, 198t, 202t

epoetin alfa (Procrit), 190-199, 191t, 192f-193f, 196f-197f, 198t

eprosartan (Teveten), 162t

ferric gluconate, 200-204, 200t, 202f

ferric saccharate, 200t

Ferritin, 202-204, 202t

Ferlecit, 200-204, 200t

Specific drugs, drug agents, and drug classes (*continued*)

furosemide, 247t
gemfibrozil, 140t-141t
glycinexylidide, 248t
heparin, 230-232, 231t
hydroxyhexamide, 248t
Imferon, 200-204, 200t
INFeD, 200-204, 200t
insulin, 148t, 247-249, 250t-251t
irbesartan (Avapro), 89-92, 90f-91f, 93-97, 96f, 162t, 165
iron dextran injections, 200-204, 200t
iron saccharate, 200-204, 200t
iron sucrose injections, 200-204, 200t, 202f
lanthanum carbonate, 218-225, 219t
laxitives, 250t-251t
lidocaine, 248t
lisinopril (Prinivil and Zestril), 120-122, 121f-131f, 162t
loop diuretics, 172
losartan (Cozaar), 92-93, 125-126, 126f, 162t, 165
magaldrate, 218-225, 219t
meperidine, 248t
methotrexate, 247t
metolazone, 247t
metoprolol, 123-124, 123f, 124t
mexiletine, 247t
moexipril (Univasc), 162t
multiple drugs, 250t-251t
n-acetylprocainamide, 248t
nicotinic acid, 140t-141t
nitroprusside, 248t
normeperidine, 248t
NSAIDs, 164, 170, 230-232, 231t
olmesartan (Benicar), 162t
oxazepam, 248t
oxypurinol, 248t
paricalcitol, oral, 224-225, 224t
penicillins, 247t, 250t-251t
perindopril (Aceaon), 162t
phenytoin, 247t, 250t-251t
phosphate binders, 218-225, 219t
potassium-sparing diuretics, 230-232, 231t, 250t-251t
probenecid, 247t

Specific drugs, drug agents, and drug classes (*continued*)

procainamide, 248t
propranolol, 248t, 250t-251t
quinapril (Accupril), 162t
RAAS blockers, 115, 159-176. *See also* RAAS (renin-angiotensin-aldosterone system) blockades.
ramipril (Altace), 117, 120f, 122-124, 123f, 124t, 162t
rifampin, 248t
salicylates, 247t
sodium ferric gluconate complex in sucrose injections, 200-204, 200t
statins, 140t-141t
steroids, 250t-251t
sulfonamides, 247t-248t
telmisartan (Micardis), 162t
tetracyclines, 250t-251t
thiazide diuretics, 128, 172
thiocyanate, 248t
trandolapril, 125-126, 126f
triamterene, 247t
valsartan (Divan), 162t
vasodilators, 164
Venofer, 200-204, 200t
warfarin, 247t
Stages, CKD, 16-17, 17t, 266t-267t
Statins, 140t-141t
Steps, dosing, 249-254. *See also* Drug-dosing considerations.
Steroids, 250t-251t
Structural abnormalities, 13-16
Studies, research. *See* Clinical trials and research studies.
Sulfonamides, 247t-248t
Summary concepts. *See* Fundamental concepts.
Sys-Eur (Systolic Hypertension in Europe Multicentre Trial), 114f
Systolic Hypertension in Europe Multicentre Trial. *See* Sys-Eur (Systolic Hypertension in Europe Multicentre Trial).
Target Hb levels, 189
Telmisartan (Micardis), 162t
Tetracyclines, 250t-251t

Teveten (eprosartan), 162t
Therapeutic lifestyle changes (TLCs), 144t
Therapies, 237-254
 diet and nutritional therapies, 237-244
 drug-dosing considerations, 245-254
Thiazide diuretics, 128, 172
Thiocyanate, 248t
Thrombogenic factors, 137t
Thrombogenic markers, 152
Trandolapril, 125-126, 126f
Treatment intensification risk factors, 126-131, 127t,
 128f-131f
Trials, clinical. *See* Clinical trials and research studies.
Triamterene, 247t
Twenty-four-hour creatinine clearance, 19
Type 1 diabetes mellitus, 67
Type 2 diabetes mellitus, 67, 71

UKPDS (United Kingdom Prospective Diabetes Study),
 85-89, 86t-88t
Univasc (moexipril), 162t
Urinary sediment, abnormal, 15
USRDS (United States Renal Data System), 37-48

Valsartan (Divan), 162t
Variable rates, disease progression, 55-58, 58f
Vascular access and AVF, 229-232
 AVF, 233-236
 AVGs and, 229, 236
 fundamental concepts for, 233
 hemodialysis access evaluations, 233-236, 234f
 reference resources for, 236
 USRDS data for, 233
Vasodilators, 164
Vasotec (enalapril), 162t
Venofer, 200-204, 200t
Vitamin and mineral requirements, 243
Vitamin D supplementation, 220-222, 221t

Warfarin, 247t
Weight, obesity, and metabolic syndrome, 147-151, 148t

Zestril (lisinopril), 120-122, 121f-131f, 162t

